KRAS and non-small cell lung carcinoma: Thus, additional studies with more uniform protocols are needed to answer the questions we currently encounter (i.e., which chemotherapeutic drugs and immunotherapy regimens are more appropriate for the KRAS‐mutant NSCLC patients).